Stock Alert: Mersana Therapeutics Down 6%

股票警告:Mersana Therapeutics下跌6%

2020-09-16 04:33:53 RTTNews

本文共297个字,阅读需1分钟

Shares of Mersana Therapeutics Inc. are losing more than 6 percent or $1.51 in Tuesday's morning trade at $22.66 despite no company-centric news that could influence the stock. Cambridge, Massachusetts-based Mersana Therapeutics is a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate or ADC targeting cancers. The company's lead drug candidate is XMT-1536, which is in the expansion portion of a phase I proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. Mersana Therapeutics has traded in a range of $1.32 to $24.97 in the past 52 weeks. For comments and feedback contact: editorial@rttnews.com Business News
Mersana Therapeutics Inc.的股票在周二上午的交易中下跌超过6%或1.51美元,报22.66美元,尽管没有任何以公司为中心的消息可能影响该股票。 总部位于马萨诸塞州剑桥的Mersana Therapeutics是一家临床阶段生物制药公司,专注于针对癌症的抗体药物缀合物或ADC的开发。该公司的主要候选药物是XMT-1536,该药物正处于卵巢癌和非小细胞肺癌患者的I期概念验证临床研究的扩展部分。 Mersana Therapeutics在过去52周的交易区间为1.32美元至24.97美元。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文